Tumor-targeted interferon-alpha delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis.

[1]  N. Ferrara,et al.  Role of myeloid cells in tumor angiogenesis and growth. , 2008, Trends in cell biology.

[2]  M. Danks,et al.  Stem and progenitor cell-mediated tumor selective gene therapy , 2008, Gene Therapy.

[3]  G. Ahn,et al.  Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. , 2008, Cancer cell.

[4]  S. Vandenberg,et al.  HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. , 2008, Cancer cell.

[5]  Z. Werb,et al.  GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. , 2008, Cancer cell.

[6]  R. Eils,et al.  Systemic spread is an early step in breast cancer. , 2008, Cancer cell.

[7]  L. Naldini,et al.  Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. , 2007, Trends in immunology.

[8]  G. Willimsky,et al.  The adaptive immune response to sporadic cancer , 2007, Immunological reviews.

[9]  Luigi Naldini,et al.  Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. , 2007, Blood.

[10]  A. Diefenbach,et al.  Dendritic cells prime natural killer cells by trans-presenting interleukin 15. , 2007, Immunity.

[11]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[12]  R. Medzhitov,et al.  Type I interferons in host defense. , 2006, Immunity.

[13]  L. Naldini,et al.  Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. , 2006, Biochimica et biophysica acta.

[14]  C. Bordignon.  Stem-cell therapies for blood diseases , 2006, Nature.

[15]  L. Naldini,et al.  Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer , 2006, Nature Medicine.

[16]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[17]  R. Kerbel,et al.  Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. , 2005, Blood.

[18]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[19]  L. Naldini,et al.  Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[20]  Hideo Negishi,et al.  IRF-7 is the master regulator of type-I interferon-dependent immune responses , 2005, Nature.

[21]  T. Blankenstein.  The role of tumor stroma in the interaction between tumor and immune system. , 2005, Current opinion in immunology.

[22]  A. Corti,et al.  Targeted delivery of IFNgamma to tumor vessels uncouples antitumor from counterregulatory mechanisms. , 2005, Cancer research.

[23]  E. Medico,et al.  Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.

[24]  F. Belardelli,et al.  Role of Cross-Talk between IFN-α-Induced Monocyte-Derived Dendritic Cells and NK Cells in Priming CD8+ T Cell Responses against Human Tumor Antigens1 , 2004, The Journal of Immunology.

[25]  E. Fuchs,et al.  Hematopoietic stem cell transplant as a platform for tumor immunotherapy. , 2004, Current opinion in molecular therapeutics.

[26]  Jeffrey W Pollard,et al.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. , 2003, The American journal of pathology.

[27]  S. Parmar,et al.  Interferons: mechanisms of action and clinical applications , 2003, Current opinion in oncology.

[28]  G. Lesinski,et al.  The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .

[29]  L. Naldini,et al.  Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells , 2003, Nature Medicine.

[30]  C. Bucana,et al.  Administration of optimal biological dose and schedule of interferon alpha combined with gemcitabine induces apoptosis in tumor-associated endothelial cells and reduces growth of human pancreatic carcinoma implanted orthotopically in nude mice. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  N. Schmitz,et al.  Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe , 2002, Bone Marrow Transplantation.

[32]  J. Kirkwood,et al.  Interferon-alpha in tumor immunity and immunotherapy. , 2002, Cytokine & growth factor reviews.

[33]  M. Grace,et al.  Interferon‐α as an immunotherapeutic protein , 2002, Journal of Leukocyte Biology.

[34]  H. Schluesener,et al.  The allograft inflammatory factor‐1 family of proteins , 2002, FEBS letters.

[35]  K. Alitalo,et al.  Tie receptors: new modulators of angiogenic and lymphangiogenic responses , 2001, Nature Reviews Molecular Cell Biology.

[36]  Andrew V. Nguyen,et al.  Colony-Stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy , 2001, The Journal of experimental medicine.

[37]  C. Dinney,et al.  Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  G. Stark,et al.  How cells respond to interferons. , 1998, Annual review of biochemistry.

[39]  C. Bucana,et al.  Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration. , 1998, Cancer research.

[40]  L. Pfeffer.  Biologic activities of natural and synthetic type I interferons. , 1997, Seminars in oncology.

[41]  P. Salmon,et al.  Pharmacokinetics and pharmacodynamics of recombinant human interferon-beta in healthy male volunteers. , 1996, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[42]  V. Maino,et al.  Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations , 1995, The Journal of experimental medicine.

[43]  J U Gutterman,et al.  Cytokine therapeutics: lessons from interferon alpha. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[44]  E. Borden,et al.  Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. , 1987, Cancer research.

[45]  F. Balkwill,et al.  Effects of mouse interferon on human tumour xenografts in the nude mouse host , 1986, International journal of cancer.

[46]  I. Gresser,et al.  Increased survival in mice inoculated with tumor cells and treated with interferon preparations. , 1969, Proceedings of the National Academy of Sciences of the United States of America.

[47]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[48]  B. Beutler,et al.  TYPE I INTERFERONS (/) IN IMMUNITY AND AUTOIMMUNITY , 2005 .

[49]  L. Naldini,et al.  Transduction of a gene expression cassette using advanced generation lentiviral vectors. , 2002, Methods in enzymology.